fingolimod hydrochloride has been researched along with Cancer of Skin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaughan, M; Lally, A; McGuigan, C; O'Higgins, L | 1 |
| Gębka-Kępińska, B; Sowa, P; Zięba, N | 1 |
| Che, Y; Kim, YH; Lock, CB; Narala, S; Rieger, KE; Saleem, A | 1 |
| Carbone, ML; De Giglio, L; Failla, CM; Lacal, PM; Mazzanti, C; Messinese, S; Pagnanelli, G; Persechino, S; Pozzilli, C | 1 |
| Ekobena, P; Ivanyuk, A; Livio, F | 1 |
| Calvi, A; Carandini, T; De Riz, M; Galimberti, D; Ghezzi, L; Lecchi, E; Maurichi, A; Pellegrinelli, A; Pietroboni, A; Scarioni, M; Scarpini, E | 1 |
| Billings, SD; Cohen, JA; Hudgens, CW; Ko, JS; Mahajan, KR; Tetzlaff, MT | 1 |
| Appel, S; Kucuk, N; Milo, R; Nitsan, Z; Osherov, M; Tichmanovich, N | 1 |
| Boes, CJ; Colgan, JP; Flanagan, EP; Howard, MT; Stitt, DW | 1 |
| Connolly, A; Grandi, V; Palmer, R; Stefanato, CM; Weir, A; Whittaker, S | 1 |
| Bastien, M; Cavalcanti, A; Chochon, F; Lubetzki, C; Robert, C; Routier, E; Thomas, M; Velter, C | 1 |
| Bugnon, O; Mazellier, S; Michiels, JF; Michiels, Y | 1 |
| Akay, EM; Cohen, SN; Evangelou, N; Samaraweera, AP | 1 |
| Haebich, G; Mughal, A; Tofazzal, N | 1 |
| Cohen, V; Friedmann, D; Provost, N; Saber, M | 1 |
| Antoniou, C; Economidi, A; Karampidou, K; Katsavos, S; Marinos, L; Matoula, T; Nasis, G; Nikolaou, V; Stratigos, A | 1 |
| Gräfe, R; Hildebrandt, U; Papathemeli, D; Ulrich, J; Zettl, UK | 1 |
| Barnett, MH; Beadnall, HN; Gill, AJ; Riminton, S | 1 |
| Guo, M; Robinson, CL | 1 |
| Braun, R; Conzett, KB; Dummer, R; French, LE; Hofbauer, GF; Jelcic, I; Kamarachev, J; Kolm, I; Linnebank, M | 1 |
3 review(s) available for fingolimod hydrochloride and Cancer of Skin
| Article | Year |
|---|---|
BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Skin Neoplasms | 2022 |
Multiple Sclerosis Treatment and Melanoma Development.
Topics: Antirheumatic Agents; Biomarkers; Biopsy; Disease Susceptibility; Female; Fingolimod Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multiple Sclerosis; Natalizumab; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2020 |
[Pharmacovigilance update].
Topics: Adenosine Monophosphate; Alanine; Cleft Lip; Contraindications, Drug; COVID-19 Drug Treatment; Cytokine Release Syndrome; Female; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Leiomyoma; Norpregnadienes; Pharmacokinetics; Pharmacovigilance; Pregnancy; Ranitidine; Safety-Based Drug Withdrawals; Skin Neoplasms | 2021 |
17 other study(ies) available for fingolimod hydrochloride and Cancer of Skin
| Article | Year |
|---|---|
Skin care advice to patients with multiple sclerosis on Fingolimod treatment at increased risk of skin malignancy-room for improvement?
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Skin Care; Skin Neoplasms | 2022 |
Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases.
Topics: Fingolimod Hydrochloride; High-Throughput Nucleotide Sequencing; Humans; Multiple Sclerosis; Mycosis Fungoides; Skin Neoplasms | 2023 |
Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Topics: Carcinoma, Merkel Cell; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms | 2017 |
Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.
Topics: Carcinoma, Merkel Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Merkel cell polyomavirus; Middle Aged; Multiple Sclerosis; Polyomavirus Infections; Skin Neoplasms | 2017 |
Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Mycosis Fungoides; Skin; Skin Neoplasms; Treatment Outcome | 2018 |
A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Topics: Aged; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Multiple Sclerosis; Skin Neoplasms | 2018 |
Primary cutaneous CD30
Topics: Biopsy; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Skin; Skin Neoplasms; T-Lymphocytes | 2018 |
Melanoma during fingolimod treatment for multiple sclerosis.
Topics: Back; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis; Natalizumab; Risk Factors; Skin Neoplasms | 2019 |
Detection of a new melanoma in a patient treated with fingolimod.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nevus, Pigmented; Skin Neoplasms; Treatment Outcome; Withholding Treatment | 2019 |
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphomatoid Papulosis; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms | 2016 |
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
Topics: Adult; Ankle; Female; Fingolimod Hydrochloride; Humans; Melanoma; Melanoma, Cutaneous Malignant; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms | 2016 |
Lymphomatoid papulosis and fingolimod-A new connection?
Topics: Fingolimod Hydrochloride; Humans; Lymphomatoid Papulosis; Skin Neoplasms | 2016 |
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Topics: Fingolimod Hydrochloride; Humans; Lymphomatoid Papulosis; Multiple Sclerosis; Skin Neoplasms | 2016 |
Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Middle Aged; Multiple Sclerosis; Skin Neoplasms | 2016 |
Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
Topics: Carcinoma, Merkel Cell; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms | 2016 |
Fingolimod (Gilenya) and melanoma.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multiple Sclerosis; Skin Neoplasms | 2016 |
Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Multiple Sclerosis; Propylene Glycols; Skin Neoplasms; Sphingosine | 2011 |